MetaCap

Pliant Therapeutics (PLRX) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 41.4% versus a loss of 61.6%. Over five years, TLPH leads with a -94.0% price change compared with -95.9% for PLRX. Talphera is the larger company by market cap ($40.8 million vs $36.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLRX-61.61%TLPH-41.40%
+13%-26%-65%
Nov 21, 20251 yearNov 20, 2026
PLRX-96.03%TLPH-94.55%
+144%+18%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLRX versus TLPH key metrics
MetricPLRXTLPH
Share price$0.5951$0.7852
Market cap$36.89M$40.80M
1-day change-4.02%+6.25%
YTD return-51.22%-31.12%
1-year return-61.61%-41.40%
5-year return-95.89%-93.96%
EPS (TTM)$-1.46$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$28.00K
Net income (latest FY)$-149.34M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$1.67$1.57
52-week low$0.5719$0.69
Distance from 52-week high-64.37%-49.99%
Analyst consensusnonenone
Avg. price target upside+236.08%+298.62%
Average volume408.93K144.13K
Shares outstanding61.99M51.96M
Employees4912
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed PLRX by 20.2 percentage points over the past year.

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

PLRX vs TLPH FAQ

Which is bigger, Pliant Therapeutics or Talphera?

Talphera (TLPH) is larger, with a market capitalization of $40.80M compared with $36.89M for Pliant Therapeutics (PLRX).

Which stock has performed better over the past year, PLRX or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.

Are Pliant Therapeutics and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons